Additionally, increased expression of several PSMs was strongly linked to the progression from chronic myelogenous leukemia (CML) (PSMA6, PSMB4, PSMD1/3) [28,29], Fanconi anemia (FA) (PSME1) [30], and myelodysplastic syndromes (MDS) (PSMB5) to AML [31], as well as to poor clinical outcomes (PSMD3, PSMD2, PSMC1–6, PSMB10, PSMB8, PSMA7, PSMD4) in AML [15,32,33,34,35,36,37,38,39,40]. Here, PSMA6 is linked to myelodysplastic syndrome.